← Back to Search

#HerHeart tool for Cardiovascular Disease

N/A

Waitlist Available

Led By Holly Gooding, MD

Research Sponsored by Emory University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 3 month post-enrollment

Awards & highlights

Study Summary

This trial will test how well a web tool called #HerHeart works in helping adolescent and young adult women and their healthcare providers communicate about heart health.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 3 month post-enrollment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 3 month post-enrollment

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 3 month post-enrollment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

#HerHEART Risk Score in AYA From Baseline

Alcohol Consumption

Cereal Fiber

+7 more

Secondary outcome measures

BMI From Baseline

Diastolic Blood Pressure (BP) From Baseline

Systolic Blood Pressure (BP) From Baseline

Trial Design

1Treatment groups

Experimental Treatment

Group I: AYA participantsExperimental Treatment1 Intervention

AYA participants will complete a brief initial survey consisting of demographic information and the Visual Analog Scale (VAS) and the #HerHeart tool in clinic. AYA participants will the rate the usability of the #HerHeart tool using the Website Analysis and Measurement Inventory (WAMMI), the likelihood they would recommend the app to their friends, and the likelihood of behavior change. AYA participants will then be offered the opportunity to continue into the 3-month intervention phase.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

#HerHeart tool

2022

N/A

~60

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

National Heart, Lung, and Blood Institute (NHLBI)NIH

3,836 Previous Clinical Trials

47,850,835 Total Patients Enrolled

Emory UniversityLead Sponsor

1,638 Previous Clinical Trials

2,560,472 Total Patients Enrolled

Holly Gooding, MDPrincipal InvestigatorEmory University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current population size of participants for this clinical investigation?

"Affirmative. The clinicaltrial.gov portal confirms that this trial is still recruiting, which began on July 1st 2022 and was recently edited on November 10th 2022. 60 participants are needed across two medical centres to complete the study."

Answered by AI

Are enrollment efforts for this trial ongoing at present?

"According to clinicaltrials.gov, this ongoing study is searching for participants with recruitment beginning on July 1st 2022 and the most recent update being November 10th 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Incorporating CV Risk Assessment in AYA Visits

Holly Gooding 2022. "Incorporating CV Risk Assessment in AYA Visits". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05384834.